Research · Sep 3, 2026
[FUL] H.B. Fuller Thesis 2026: Adhesives-and-Sealants-and-Specialty-Chemicals Compounder
H.B. Fuller Company (NYSE: FUL), headquartered in St. Paul, Minnesota, is an Adhesives-and-Sealants-and-Specialty-Chemicals + emerging-multi-cycle-Hygiene-Health-and-Consumables-and-Engineering-Adhesives leader providing distinctive multi-cycle Hygiene-Health-and-Consumables-Adhesives + emerging-Engineering-Adhesives + emerging-Construction-Adhesives + emerging-Industrial-Adhesives + emerging-Specialty-Coatings + emerging-Latin-America-Adhesives services to substantial multi-cycle US-and-emerging-multi-cycle-international Adhesives-and-Sealants-Customer + multi-cycle-emerging-Diaper-and-Feminine-Hygiene-Manufacturer + multi-cycle-emerging-Packaging-Manufacturer + multi-cycle-emerging-Electronics-Assembly + multi-cycle-emerging-Transportation-and-Heavy-Equipment-Manufacturer + multi-cycle-emerging-Construction-Tile-and-Flooring + multi-cycle-emerging-Furniture-and-Woodworking customer base. The company has distinctive multi-cycle H.B.-Fuller-and-St-Paul-MN-and-Adhesives-and-Sealants heritage: founded 1887 as H.B.-Fuller-Company-Harvey-Benjamin-Fuller-Founder-Family; 1968 NYSE H.B.-Fuller-IPO; 1990-2018 multi-cycle-substantial-Specialty-Chemicals-acquisitions; 2017 substantial Royal-Adhesives-and-Sealants-acquired ($1.575B providing emerging-multi-cycle-Engineering-and-Industrial-Adhesives); 2018 substantial Tonsan-China-Adhesives-acquired; 2019 substantial Adecol-Latin-America-Adhesives; 2023 Celeste-Mastin-CEO; 2024 substantial Specialty-Adhesives-and-Adhesives-acquisitions; multi-cycle-disciplined-bolt-on-Specialty-Adhesives-and-Sealants-acquisitions. FY2025 (Dec-FYE) closes with selected various aggregate revenue ~$3.45-3.70B (~0-5% YoY-growth + emerging-multi-cycle-Hygiene-Health-and-Consumables-and-Engineering-Adhesives-and-Construction-and-Latin-America-and-Asia-Pacific-growth), adjusted EBITDA ~$580-680M (~17-19% margins reflecting Specialty-Adhesives-and-Sealants economics), adjusted EPS ~$4.30-5.05, net debt ~$1.60-1.80B (~2.5-3.0x leverage), and ~53-55M shares outstanding under President & CEO Celeste Mastin. The Hygiene-Health-and-Consumables-and-Engineering-Adhesives-and-Construction-Adhesives-and-Industrial-Adhesives franchise deep-dive covers distinctive multi-cycle ~7,500+ employees + ~Globally-Positioned-Adhesives-and-Sealants-Manufacturing-Facilities, Hygiene-Health-and-Consumables ~30-34% revenue + Engineering-Adhesives ~28-32% revenue + Construction-Adhesives ~16-20% revenue + Industrial-Adhesives-and-Other ~18-22% revenue, 2017-Royal-Adhesives-and-Sealants-acquired + 2018-Tonsan-China + 2019-Adecol-Latin-America + 2024-Specialty-Adhesives-acquisitions transformational-platform, emerging-multi-cycle US-and-international-Adhesives-and-Sealants structural-tailwinds, competing in Adhesives-and-Sealants space with 3M, Solventum/3M-spin-off, Henkel, Sika/MBCC-Group, Bostik/Arkema, Arkema, DuPont, Dow, Eastman Chemical, Avery Dennison, Berry Global/Magnera, Pidilite, Mapei, RPM International, Master Builders Solutions/Sika, Soudal, Tremco-Illbruck/RPM, Adhesives Research, Lord/Parker-Hannifin, Permabond, and private-equity-Apollo-Carlyle-Bain-KKR-Blackstone-CDR-Veritas-Genstar-American-Securities-CCMP-SK-Capital-Cinven-Lone-Star-Advent-TPG-HM-Brookfield-Ardian-GTCR-Wendel-EQT-Bregal-Gilde-Permira-Onex-Madison-Dearborn-Investindustrial. The Celeste-Mastin + Dividend-King + multi-decade compounder thesis deep-dive covers Celeste-Mastin-CEO (since 2023, ~25+ year longtime-H.B.-Fuller-and-Former-3M-and-Bemis-and-Bryan-Cave-veteran) expertise, 1887-H.B.-Fuller-Company-Harvey-Benjamin-Fuller-Founder-Family + 1968-NYSE-IPO + 2017-Royal-Adhesives-and-Sealants + 2018-Tonsan-China + 2019-Adecol-Latin-America + 2024-Specialty-Adhesives transformational-platform, multi-cycle reliable-and-emerging-growing-dividend-Dividend-King-with-56-consecutive-annual-dividend-increases (~$0.92/yr, ~1.2-1.7% yield, ~17-22% payout) + multi-cycle-substantial-share-buyback (~$50-150M/yr). Capital position is IG-equivalent (Ba1/BB+ to Baa3/BBB- ~2.5-3.0x leverage). At ~$55-75 per share, equity value ~$2.95-4.05B, EV ~$4.55-5.85B, providing ~12-17x EPS and ~7-10x EV/EBITDA.